A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

Phase 3CompletedNCT00219063

Novartis844 enrolled

Overview

To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

844

Conditions

Hypertension

Interventions

aliskirenDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Patients with essential hypertension * Patients who are eligible and able to participate in the study Exclusion Criteria * Severe hypertension * History or evidence of a secondary form of hypertension * History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion exclusion criteria also apply.

Locations (1)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Outcomes

Primary Outcomes

Change from baseline in diastolic blood pressure after 26 weeks

Secondary Outcomes

Change from baseline in systolic blood pressure after 26 weeks

Change from baseline in diastolic blood pressure after 6 weeks and 12 weeks

Change from baseline in systolic blood pressure after 6 weeks and 12 weeks

Blood pressure control target of < 140/90 mmHg after 6, 12, and 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.